Nanoscope's Multi-Characteristic Opsin (MCO) mutation-agnostic gene therapy platform is designed to restore vision in patients blinded by retinal degenerative diseases. The company is conducting a multi-site randomized and sham-controlled Phase 2b clinical trial for retinitis pigmentosa (NCT04945772). Results are expected in Q1 2023. The company also expects to begin Phase 2 clinical trials for Stargardt macular degeneration in Q2-2022. MCO therapy received orphan drug designations from the FDA for RP and Stargardt.